Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
NeuroRx has filed an investigational protocol with the U.S. FDA under CTAP to conduct a Phase 2/3 trial of inhaled RLF-100 as a treatment for patients with non-acute lung injury caused by COVID-19.